肝细胞癌相关性骨骼肌减少症的研究近况

沈素雅; 黄建钊; 刘延; 刘江伟; 张旭阳; 叶琨琦; 潘宁波

doi:10.3969/j.issn.1001-5256.2020.07.042

肝细胞癌相关性骨骼肌减少症的研究近况

DOI: 10.3969/j.issn.1001-5256.2020.07.042

1. 贵州医科大学临床医学院
2. 贵州省人民医院肝胆外科

基金项目:

贵州省人民医院国家自然科学基金培育基金(黔科合平台人才[2018]5764-15)；

详细信息

中图分类号: R735.7;R685
计量
- 文章访问数: 624
- HTML全文浏览量: 22
- PDF下载量: 122
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Research advances in hepatocellular carcinoma-related sarcopenia

1. School of Clinical Medicine, Guizhou Medical University, Guiyang 550000, China
2. Department of Hepatobiliary Surgery, Guizhou Provincial People’s Hospital, Guiyang 550000, China

Research funding:

摘要

摘要:
肝细胞癌(HCC)是常见的恶性肿瘤之一,HCC患者通常合并肝硬化,即使经过治愈性治疗,5年复发率仍然很高,预后较差。近年来,骨骼肌减少症作为各类恶性肿瘤的预后不良因素而备受关注。然而,国内对骨骼肌指数与HCC预后之间的相关性研究较少。国外研究表明,骨骼肌减少症可能是HCC患者预后不良的危险因素。对HCC相关性骨骼肌减少症病因及可能的发生机制、干预措施如营养补充、适当的运动、药物治疗等进行详细综述,以期为国内开展相关研究提供借鉴。
- 癌,肝细胞 /
- 骨骼肌减少症 /
- 预后
Abstract:
Hepatocellular carcinoma( HCC) is a common malignant tumor and patients with HCC often have liver cirrhosis,with an extremely high 5-year recurrence rate and poor prognosis even after curative treatment. In recent years,sarcopenia has attracted more and more attention as a poor prognostic factor for various malignant tumors; however,there is still a lack of studies on the association between skeletal muscle index and prognosis of HCC in China. Evidence in foreign countries has shown that sarcopenia may be an a negative prognostic factor for HCC patients. This article reviews the etiology and possible pathogenesis of HCC-related sarcopenia and related intervention measures including nutritional supplementation,appropriate physical exercise,and medication,in order to provide a reference for related studies in China.
- carcinoma,hepatocellular /
- skeletal muscle depletion /
- prognosis

HTML全文

参考文献(40)

[1] HENDRICKSON PG,OLSON M,LUETKENS T,et al.The promise of adoptive cellular immunotherapies in hepatocellular carcinoma[J].Oncoimmunology,2020,9(1):1673129．

[2] LEE J,CHO Y,PARK S,et al.Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with radiotherapy[J].Front Oncol,2019,9:1075．

[3]NJEI B,ROTMAN Y,DITAH I,et al.Emerging trends in hepatocellular carcinoma incidence and mortality[J].Hepatology,2015,61(1):191-199．

[4] LU SD,LI L,LIANG XM,et al.Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy[J].Expert Rev Gastroenterol Hepatol,2019,13(11):1077-1088．

[5]PRADO CM,CUSHEN SJ,ORSSO CE,et al.Sarcopenia and cachexia in the era of obesity:Clinical and nutritional impact[J].Proc Nutr Soc,2016,75(2):188-198．

[6]WALLENGREN O,IRESJ BM,LUNDHOLM K,et al.Loss of muscle mass in the end of life in patients with advanced cancer[J].Support Care Cancer,2015,23(1):79-86．

[7]PRADO CM,LIEFFERS JR,MCCARGAR LJ,et al.Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts:A populationbased study[J].Lancet Oncol,2008,9(7):629-635．

[8] CHOI Y,OH DY,KIM TY,et al.Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy,independent of body mass index[J].PLo SOne,2015,10(10):e0139749．

[9] MIYAMOTO Y,BABA Y,SAKAMOTO Y,et al.Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer[J].Ann Surg Oncol,2015,22(8):2663-2668．

[10]HARIMOTO N,SHIRABE K,YAMASHITA YI,et al.Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma[J].Br J Surg,2013,100(11):1523-1530．

[11] YABUSAKI N,FUJII T,YAMADA S,et al.Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection[J].Int J Surg,2016,30:136-142．

[12] KOBAYASHI T,KAWAI H,NAKANO O,et al.Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies[J].BMC Cancer,2018,18(1):756．

[13] Rosenberg IH.Summary comments:Epidemiological and methodological problems in determining nutritional status of older persons[J].Am J Clin Nutr,1989,50:1231-1233．

[14] CRUZ-JENTOFT AJ,BAHAT G,BAUER J,et al.Sarcopenia:Revised European consensus on definition and diagnosis[J].Age Ageing,2019,48(1):16-31．

[15]FANG L,JING X,TIAN ZB.A review of the relationship between sarcopenia and cirrhosis[J].Parenter Enteral Nutr,2018,25(5):308-312.(in Chinese)房良，荆雪，田字彬．肌肉减少症与肝硬化的临床研究进展[J]．肠外与肠内营养，2018,25(5):308-312．

[16]CHEN LK,LIU LK,WOO J,et al.Sarcopenia in Asia:Consensus report of the Asian Working Group for Sarcopenia[J].Am Med Dir Assoc,2014,15(2):95-101．

[17] SANTILLI V,BERNETTI A,MANGONE M,et al.Clinical definition of sarcopenia[J].Clin Cases Miner Bone Metab,2014,11(3):177-180．

[18]ZHANG FF,LU XQ.Sarcopenia and cancer chemotherapy[J/CD].Electron J Metab Nutr Cancer,2019,6(1):110-115.(in Chinese)张付峰，卢晓琴．肌肉减少症与肿瘤化疗[J/CD]．肿瘤代谢与营养电子杂志，2019,6(1):110-115．

[19] VORON T,TSELIKAS L,PIETRASZ D,et al.Sarcopenia impacts on short-and long-term results of hepatectomy for hepatocellular carcinoma[J].Ann Surg,2015,261(6):1173-1183．

[20] TAKAGI K,YAGI T,YOSHIDA R,et al.Sarcopenia and American Society of Anesthesiologists Physical Status in the assessment of outcomes of hepatocellular carcinoma patients undergoing hepatectomy[J].Acta Med Okayama,2016,70(5):363-370．

[21] JIANG XL,LI YC.Correlation between intestinal dysbacteriosis and primary liver cancer[J].China Health Nutrition,2019,29(29):266.(in Chinese)蒋小丽，李阳超．肠道菌群失调与原发性肝癌的相关性分析[J]．中国保健营养，2019,29(29):266．

[22] LIU QQ,DONG GL,JING ZL,at al.Study on characteristics and influencing factors of CT perfusion imaging of pancreas under liver cirrhosis.[J].J Pract Radiol,2018,34(1):42-46.(in Chinese)刘倩倩，董国礼，敬宗林，等．肝硬化对胰腺微循环影响的CT灌注成像研究[J]．实用放射学杂志，2018,34(1):42-46．

[23]ZHAO WH,LIU XL,LI HW,et al.Features and clinical significance of nutritional metabolism in patients with primary liver cancer[J].J Clin Hepatol,2019,35(4):905-907.(in Chinese)赵文昊，刘雪莲，李宏伟，等．原发性肝癌的营养代谢特点及意义[J]．临床肝胆病杂志，2019,35(4):905-907．

[24] Chinese Society for Oncological Nutrition and Supportive Care,Chinese Anti-Cancer Association.Guidelines for nutritional therapy for sarcopenia[J/CD].Electron J Metab Nutr Cancer,2015,2(3):32-36.(in Chinese)中国抗癌协会肿瘤营养与支持治疗专业委员会．肌肉减少症营养治疗指南[J/CD]．肿瘤代谢与营养电子杂志，2015,2(3):32-36．

[25]FROST RA,LANG CH.Multifaceted role of insulin-like growth factors and mammalian target of rapamycin in skeletal muscle[J].Endocrinol Metab Clin North Am,2012,41(2):297-322．

[26] KHOSHNOOD A,NASIRI TOOSI M,FARAVASH MJ,et al.A survey of correlation between insulin-like growth factor-I(igf-I)levels and severity of liver cirrhosis[J].Hepat Mon,2013,13(2):e6181．

[27] IBEBUNJO C,EASH JK,LI C,et al.Voluntary running,skeletal muscle gene expression,and signaling inversely regulated by orchidectomy and testosterone replacement[J].Am J Physiol Endocrinol Metab,2011,300(2):e327-e340．

[28]GROSSMANN M,HOERMANN R,GANI L,et al.Low testosterone levels as an independent predictor of mortality in men with chronic liver disease[J].Clin Endocrinol(Oxf),2012,77(2):323-328．

[29]FIELDING RA,VELLAS B,EVANS WJ,et al.Sarcopenia:An undiagnosed condition in older adults.Current consensus definition:Prevalence,etiology,and consequences.International working group on sarcopenia[J].J Am Med Dir Assoc,2011,12(4):249-256．

[30]LI XC,WANG HW,LI CX.Present situation and prospect of comprehensive treatment of hepatocellular carcinoma[J].Chin J Dig Surg,2018,17(5):433-436.(in Chinese)李相成，王宏伟，李长贤．肝癌综合治疗的现状与展望[J]．中华消化外科杂志，2018,17(5):433-436．

[31]HU XW,DING TL,HONG ZX.Partial hepatectomy combined with radiofrequency ablation for the treatment of primary liver cancer[J].Traum Crit Med,2018,6(4):226-230.(in Chinese)胡雄伟，丁同领，洪智贤．部分肝切除术联合射频消融术治疗原发性肝癌疗效分析[J]．创伤与急危重病医学，2018,6(4):226-230．

[32] IMAI K,TAKAI K,MIWA T,et al.Rapid Depletions of subcutaneous fat mass and skeletal muscle mass predict worse survival in patients with hepatocellular carcinoma treated with sorafenib[J].Cancers(Basel),2019,11(8):1206．

[33]JONES JC,COOMBES JS,MACDONALD GA.Exercise capacity and muscle strength in patients with cirrhosis[J].Liver Transpl,2012,18(2):146-151．

[34] TAJIRI K,SHIMIZU Y.Branched-chain amino acids in liver diseases[J].Transl Gastroenterol Hepatol,2018,3:47．

[35] TIELAND M,BROUWER-BROLSMAE M,NIENABER-ROUSSEAUC.et al.Low vitamin D status is associated with reduced muscle mass and impaired physical perfomance in frail eldedy people[J].Eur J Clin Nutr,2013,67(10):1050-1055．

[36]CHEN HT,MA XL,MA JX,et al.Kinesitherapy for sarcopenia[J].Chin J Osteoporosis Bone Miner Res,2017,10(6):582-588.(in Chinese)陈恒亭，马信龙，马剑雄，等．肌肉减少症运动疗法[J]．中华骨质疏松和骨矿盐疾病杂志，2017,10(6):582-588．

[37]SINCLAIR M,GOW PJ,GROSSMANN M,et al.Review article:Sarcopenia in cirrhosis-aetiology,implications and potential therapeutic interventions[J].Aliment Pharmacol Ther,2016,43(7):765-777．

[38] GALVO DA,TAAFFE DR,SPRY N,et al.Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases:A randomized controlled trial[J].J Clin Oncol,2010,28(2):340-347．

[39]BECKER C,LORD SR,STUDENSKI SA,et al.Myostatin antibody(LY2495655)in older weak fallers:A proof-of-concept,randomised,phase 2 trial[J].Lancet Diabetes Endocrinol,2015,3(12):948-957．

[40]CAI JX,LOU HL.Sarcopenia[J/CD].Electron J Metab Nutr Cancer,2019,6(1):135-143.(in Chinese)蔡君香，楼慧玲．肌肉减少症[J/CD]．肿瘤代谢与营养电子杂志，2019,6(1):135-143.

施引文献

资源附件(0)

访问统计